Published February 21, 2018; Updated June 24, 2019
Susa Coffey, MD
Selected Reference
3. Daar E, DeJesus E, Ruane P, et al. Phase 3 randomized, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: week 48 results. In: Program and abstracts of ID Week 2017; October 4-8, 2017; San Diego, CA. Abstract LB-4.